E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy

These proof-of-concept studies validate the mode of action of E-52862, a selective sigma-1 receptor antagonist. In CPSP, E-52862 resulted in clinically meaningful pain relief. In PDN, reductions in pain intensity were seen with E-52862; high placebo response rates may have prevented differentiation between E-52862 and placebo. These findings are clinically relevant given that neuropathic pain is highly incapacitating, lacking effective treatments and representing a significant unmet medical need, and support further development of sigma-1 receptor antagonists for peripheral neuropathic pain.

Authors

Institutions

Publication Details

Journal
European Journal of Pain
Published
2024-12-04
DOI
https://doi.org/10.1002/ejp.4755
Citations
12
Primary Topic
Pain Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
3.92
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy

Adelaida Morte, Mariano Sust, V. Mayoral, Antônio Montes et al.
12 citations
European Journal of Pain
Pain Mechanisms and Treatments
3.92
article

E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy

Adelaida Morte, Mariano Sust, V. Mayoral, Antônio Montes, César Margarit, Javier Medel, Jesús Cebrecos, Didier Bouhassira, Anna Vaqué, Rafael Gálvez, F. Neira-Reina, Luz Cánovas
article en
12 citations

Abstract

These proof-of-concept studies validate the mode of action of E-52862, a selective sigma-1 receptor antagonist. In CPSP, E-52862 resulted in clinically meaningful pain relief. In PDN, reductions in pain intensity were seen with E-52862; high placebo response rates may have prevented differentiation between E-52862 and placebo. These findings are clinically relevant given that neuropathic pain is highly incapacitating, lacking effective treatments and representing a significant unmet medical need, and support further development of sigma-1 receptor antagonists for peripheral neuropathic pain.

European Journal of PainVol. 29(1)
Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Bellvitge University Hospital (ES), Vall d'Hebron Institut de Recerca (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Del Mar (ES), Hôpital Ambroise-Paré (FR), Hospital General Universitario de Alicante Doctor Balmis (ES), Hospital Universitario Puerto Real (ES), Complejo Hospitalario de Ourense (ES)
Good health and well-being
Openalex Percentile: Top 5%
Pain Mechanisms and Treatments
3.92
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.